Organoid Protein Aggregation Screening in 3D Tissue Models
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for evaluating the aggregation of proteins, such as amyloid β, in vitro do not accurately reflect the in vivo environment, leading to discrepancies between cell-free and cell-based assays, and two-dimensional cell cultures fail to replicate complex cellular interactions.
Innovation Solution
A method using organoids in a three-dimensional environment to quantify aggregating proteins labeled with optical labels, particularly quantum dots, to assess the aggregation-suppressing or aggregation-promoting effects of test substances, and a process to produce organoids suitable for disease prevention or treatment screening.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If cell-free assays are used to evaluate protein aggregation, then high-throughput screening is enabled, but the results do not accurately reflect in vivo environment
Solution Approach 1:
The patent creates organoids as three-dimensional copies of in vivo tissue environments that replicate complex cellular interactions and extracellular matrix structures. These organoid models copy the physiological conditions of the human body, allowing high-throughput screening while maintaining accuracy in evaluating protein aggregation behavior as it occurs in living systems.
Solution Approach 2:
The patent transitions from two-dimensional cell cultures to three-dimensional organoid structures. This dimensional change enables the reproduction of complex spatial relationships, cellular heterogeneity, and extracellular matrix interactions that are critical for accurate protein aggregation evaluation while maintaining screening efficiency through automated imaging and analysis systems.
2Ease of manufacture
If two-dimensional cell cultures are used, then ease of cultivation is improved, but complex signal exchange between cells and ECM cannot be reproduced
Solution Approach 1:
The patent employs three-dimensional organoid cultures that embed cells within a gel matrix, enabling complex signal exchange between cells and extracellular matrix. This three-dimensional architecture reproduces the spatial relationships and interaction pathways found in vivo, significantly improving the reliability of test results for clinical applications while maintaining manageable cultivation through standardized protocols.
Solution Approach 2:
The patent introduces a gel embedding medium as an intermediary that facilitates complex interactions between cells and the extracellular matrix. This gel matrix acts as a mediator that allows proteins to aggregate and interact with cells in a controlled three-dimensional environment, enabling reliable evaluation of aggregation effects while maintaining ease of cultivation through established organoid protocols.
3Measurement precision
If organoids in three-dimensional environment are used, then biological relevance to in vivo conditions is improved, but device complexity increases
Solution Approach 1:
The patent employs preliminary actions by pre-forming organoids through standardized protocols before aggregation evaluation. The organoids are prepared in advance with appropriate gel embedding and cellular composition, allowing the actual aggregation screening to be performed more simply. This preliminary preparation simplifies the overall device complexity while maintaining high measurement precision for aggregation evaluation.
Solution Approach 2:
The patent replaces complex mechanical systems for direct observation with optical detection methods. By using fluorescent labels and imaging systems to detect aggregated proteins within organoids, the patent simplifies the measurement system compared to direct mechanical analysis, maintaining high accuracy while reducing device complexity in the evaluation phase.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables effective screening of candidate compounds for Alzheimer's disease treatment by quantifying protein aggregation within organoids, providing a biological environment closer to in vivo conditions.
Implementation Method 1
an aggregating protein labeled with a label, a test substance, and an organoid are allowed to coexist, wherein the aggregating protein aggregated and/or deposited on a surface of the organoid and/or inside the organoid is quantified using the label as an index
Implementation Method 2
labeled with a label... quantified using the label as an index
Data Source
AI summary
The present invention aims to provide a method for screening a substance having an aggregation-suppressing activity or aggregation-promoting activity on an aggregating protein, and a method for producing an organoid and an organoid produced by this method. Specifically, the present invention relates to a method for evaluating an aggregation-suppressing activity or aggregation-promoting activity of a test substance on an aggregating protein, the method including allowing an aggregating protein labeled with a label, a test substance, and an organoid to coexist in an aqueous solution, and quantifying the aggregating protein aggregated and/or deposited on a surface of the organoid and/or inside the organoid using the label as an index; and a method for producing an organoid, including forming a spheroid by culturing a cell, embedding the obtained spheroid in a gel, and culturing the embedded spheroid in the gel.